Patrick Yerly

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Cardiac Resynchronization Therapy

Left Ventricular

Polycyclic Aromatic Hydrocarbons

Acute Heart Failure

Top Venues

Journal of clinical medicine

Circulation. Heart failure

Xenotransplantation

This page only lists publications with an associated author ORCID identifier.

Publications

Tobias Rutz, John-David Aubert, Maurice Beghetti, Eric Eeckhout, Olivier Müller, Judith Bouchardy Clement, Patrick Yerly
Atrial Septal Defect, Pulmonary Arterial Hypertension, and Diastolic Left Heart Failure: When 3 Players Come into the Game. Circulation. Heart failure 17 (5) (2024)
Tobias Rutz, John-David Aubert, Maurice Beghetti, Eric Eeckhout, Olivier Müller, Judith Bouchardy Clement, Patrick Yerly
Atrial Septal Defect, Pulmonary Arterial Hypertension, and Diastolic Left Heart Failure: When 3 Players Come into the Game. Circulation. Heart failure 17 (5) (2024)
Tobias Rutz, John-David Aubert, Maurice Beghetti, Eric Eeckhout, Olivier Müller, Judith Bouchardy Clement, Patrick Yerly
Atrial Septal Defect, Pulmonary Arterial Hypertension, and Diastolic Left Heart Failure: When 3 Players Come into the Game. Circulation. Heart failure (2024)
Nicolas Dayer, Zied Ltaief, Lucas Liaudet, Benoit Lechartier, John-David Aubert, Patrick Yerly
Pressure Overload and Right Ventricular Failure: From Pathophysiology to Treatment. Journal of clinical medicine 12 (14) (2023)
Argyro Vraka, Eleni Diamanti, Mithum Kularatne, Patrick Yerly, Frédéric Lador, John-David Aubert, Benoit Lechartier
Risk Stratification in Pulmonary Arterial Hypertension, Update and Perspectives. Journal of clinical medicine 12 (13) (2023)
Patrick Yerly, Samuel Rotman, Julien Regamey, Vincent Aubert, Stefania Aur, Matthias Kirsch, Roger Hullin, Manuel Pascual
Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation. Xenotransplantation 29 (1) (2022)
Eleni Diamanti, Vasiliki Karava, Patrick Yerly, John-David Aubert
Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension. Journal of clinical medicine 11 (1) (2021)